Directing dendritic cell immunotherapy towards successful cancer treatment.
about
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesHarnessing immunosurveillance: current developments and future directions in cancer immunotherapySialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responsesClinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.Monocytes to functional dendritic cells is often a bridge too far for cancer therapy.Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancerCurcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis.Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.The response of human dendritic cells to co-ligation of pattern-recognition receptors.Dendritic cells and their role in tumor immunosurveillance.Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.Dendritic cell-based immunotherapy in mesothelioma.Dendritic cell immunotherapy in ovarian cancer.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.mRNA-based dendritic cell vaccines.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Dendritic cell-based immunotherapy: a basic review and recent advances.Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.The gene expression profile of unstimulated dendritic cells can be used as a predictor of function.Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+ cells.How effective could laser-based approaches be in assisting dendritic cell immunotherapy?Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.Nuclear Receptor Nur77 Deficiency Alters Dendritic Cell Function
P2860
Q26772715-0781DA60-C10C-4A89-9CD4-42C06FEF8B80Q27021570-E89272BB-B96A-40DA-8568-5F0734E27DA3Q30367426-03269621-1F21-4DB3-8292-C8144B187DCFQ33427019-37AD5C99-4489-43FE-8FB1-CE0062A3C258Q34119366-701731B3-9510-4D29-8A9D-80061CBE80DDQ35546869-2180C517-A0DD-48C2-A1E9-B29A63497B6BQ36350299-909914E4-4083-4345-ACF1-22572E38A68EQ36502870-77E5E9BA-BE45-4D64-92CA-D0922F75555CQ36587730-0990AA05-609A-45CC-8CFF-FFBB3F281EA7Q36740905-884A0637-9830-4052-84E4-3D588E12D487Q37438637-43BD0F35-A06D-408F-AB4E-75EC61361FE0Q37829504-A27C9CBC-87CB-449D-B658-FDA93083DC25Q37873924-0F6956BE-2D50-45ED-A17D-2FE71F69D1E6Q37990783-3B54F4FE-14D6-44D8-83CA-2476DAF7715EQ38021625-5D753BDB-5046-4B03-85A4-AEF2BDD446BAQ38059513-FD352646-724D-4949-9EFE-1F5026E573BAQ38059514-A82D9409-E5DC-4A87-A004-4096566C031CQ38069183-E7C60599-4CE4-4EF4-9F48-54FA56013F02Q38110935-89E157C7-A34C-4DBF-B669-00D2D138D9D8Q38246769-453E48AB-65A3-44F6-B560-7D2B610D4E22Q38266149-36E1033B-E5EE-4C3B-88AD-7EE275AFB7E5Q38665350-BDA55A72-7D61-4D5C-86DE-4BB297DA72C1Q39117175-FF918221-82FB-4B84-8F07-760E144D2DABQ39566639-3423FDA1-AF8F-4032-B7C8-B1D8910B30BCQ40427880-D5A882F8-9BA4-4561-8AE6-868C3C0803A2Q41855097-2AC4F85F-614F-4F50-8F2B-D73AA36FFF1CQ42316099-E776D452-BEA1-4703-8755-585EC60FEFCEQ48356042-609AFC4E-F3F4-4A38-B435-A3A4A39ADA91Q50535283-7965426A-973B-4121-A99D-8486F1860250Q55174561-5C057C19-F3CB-48C6-8F8C-AE79E4C98B55Q58801877-8F7FE70A-2DBA-4539-9D4E-83D1815B07C2
P2860
Directing dendritic cell immunotherapy towards successful cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Directing dendritic cell immunotherapy towards successful cancer treatment.
@en
Directing dendritic cell immunotherapy towards successful cancer treatment.
@nl
type
label
Directing dendritic cell immunotherapy towards successful cancer treatment.
@en
Directing dendritic cell immunotherapy towards successful cancer treatment.
@nl
prefLabel
Directing dendritic cell immunotherapy towards successful cancer treatment.
@en
Directing dendritic cell immunotherapy towards successful cancer treatment.
@nl
P2860
P356
P1433
P1476
Directing dendritic cell immunotherapy towards successful cancer treatment.
@en
P2093
Nina Bhardwaj
Rachel Lubong Sabado
P2860
P356
10.2217/IMT.09.43
P577
2010-01-01T00:00:00Z